European regulators give a green light to "Mosquirix," the first malaria vaccine, developed by GlaxoSmithKline and the nonprofit PATH. The hosts express skepticism about the vaccine's efficacy and the involvement of the Gates Foundation. They note that the vaccine is intended for use in young children in Africa.
